Search results
Added:
1 year ago
Added:
1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had…
View more
Added:
2 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
1 year ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3…
View more
Decoding the Future of HF — Key Takeaways from 2024
Video Series
Added:
1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR…
View more
Added:
8 months ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously…
View more
Added:
2 years ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.
Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or…
View more
Added:
1 year ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating…
View more